NSCLC (Non-small Cell Lung Cancer)
Oncology
1
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
2030
REVOLUTION Medicinesdaraxonrasib
Clinical Trials (1)
Total enrollment: 420 patients across 1 trials
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Start: May 2025Est. completion: Dec 2030420 patients
Phase 3Recruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
3m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
3m ago
Office Administrator
SystImmune
3m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
14m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
17m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
17m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 420 patients
2 companies competing in this space